1. Home
  2. RMI vs WGSWW Comparison

RMI vs WGSWW Comparison

Compare RMI & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RMI
  • WGSWW
  • Stock Information
  • Founded
  • RMI 2018
  • WGSWW 2017
  • Country
  • RMI United States
  • WGSWW United States
  • Employees
  • RMI N/A
  • WGSWW 1000
  • Industry
  • RMI Finance/Investors Services
  • WGSWW Retail: Computer Software & Peripheral Equipment
  • Sector
  • RMI Finance
  • WGSWW Technology
  • Exchange
  • RMI Nasdaq
  • WGSWW Nasdaq
  • Market Cap
  • RMI N/A
  • WGSWW N/A
  • IPO Year
  • RMI N/A
  • WGSWW N/A
  • Fundamental
  • Price
  • RMI $14.07
  • WGSWW $0.15
  • Analyst Decision
  • RMI
  • WGSWW
  • Analyst Count
  • RMI 0
  • WGSWW 0
  • Target Price
  • RMI N/A
  • WGSWW N/A
  • AVG Volume (30 Days)
  • RMI 17.4K
  • WGSWW 36.6K
  • Earning Date
  • RMI 01-01-0001
  • WGSWW 02-18-2025
  • Dividend Yield
  • RMI 7.28%
  • WGSWW N/A
  • EPS Growth
  • RMI N/A
  • WGSWW N/A
  • EPS
  • RMI N/A
  • WGSWW N/A
  • Revenue
  • RMI N/A
  • WGSWW $305,450,000.00
  • Revenue This Year
  • RMI N/A
  • WGSWW N/A
  • Revenue Next Year
  • RMI N/A
  • WGSWW N/A
  • P/E Ratio
  • RMI N/A
  • WGSWW N/A
  • Revenue Growth
  • RMI N/A
  • WGSWW 50.79
  • 52 Week Low
  • RMI $13.05
  • WGSWW $0.17
  • 52 Week High
  • RMI $17.37
  • WGSWW $0.21
  • Technical
  • Relative Strength Index (RSI)
  • RMI 33.31
  • WGSWW N/A
  • Support Level
  • RMI $13.94
  • WGSWW N/A
  • Resistance Level
  • RMI $14.21
  • WGSWW N/A
  • Average True Range (ATR)
  • RMI 0.31
  • WGSWW 0.00
  • MACD
  • RMI 0.00
  • WGSWW 0.00
  • Stochastic Oscillator
  • RMI 30.14
  • WGSWW 0.00

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Share on Social Networks: